Indian Pharma Industry 2026: Beyond the 'Pharmacy of the World' Narrative
India's pharmaceutical industry is estimated at US$ 55–65 billion in FY2026, split roughly evenly between the domestic market and exports. India supplies about 20% of global generic drug volumes. The industry's next decade will be decided by how fast capital migrates to CDMO, biosimilars, and specialty.
Free Report
Indian Pharma Industry 2026: Beyond the 'Pharmacy of the World' Narrative
No spam. Instant download.
Key Findings
- 1
India's pharma industry is US$ 55–65 billion in FY26 — split roughly evenly between domestic and exports
- 2
India supplies ~20% of global generic drug volumes; exports run at US$ 27–30+ billion annually
- 3
US generics — the core export engine — face mid-to-high single digit annual price erosion
- 4
CDMO/CRDMO is the strongest structural story: global supply-chain diversification from China redirects contracts to India
- 5
API dependence on China remains high despite PLI schemes
- 6
FDA compliance track record is the single best predictor of export earnings durability
Two Markets, Two Economics
Domestic formulations (~US$ 25–28 billion): a branded-generics market growing 8–10% annually. Exports (~US$ 27–30+ billion): dominated by US generics, where economics have deteriorated for a decade.
Where Value Is Migrating
Three destinations absorb the strategic capital: CDMO/CRDMO (strongest structural story), biosimilars (wave of biologic patent expiries through 2030), and specialty/innovation.
API and the China Dependence
India's paradox: pharmacy of the world, yet dependent on China for a large share of key starting materials and APIs. Full backward integration is a decade-scale project.
The Compliance Tax
US FDA scrutiny of Indian facilities is a recurring earnings event. Quality remediation is now a permanent cost line, and the gap between companies that treat compliance as culture versus cost shows up directly in valuation multiples.
Free Download
Get the full 16-page report
Primary research, data-backed findings, and strategic recommendations — all in one PDF. Free to download.
Frequently Asked Questions
How big is the Indian pharmaceutical industry?
Approximately US$ 55–65 billion in FY2026, roughly evenly split between domestic sales and exports.
What is the CDMO opportunity for India?
Global pharmaceutical companies are diversifying development and manufacturing contracts away from China, positioning Indian contract manufacturers with strong regulatory track records to capture outsourced work.
Is the domestic Indian pharma market growing?
Yes — 8–10% annually, led by chronic therapies such as cardiac, anti-diabetic, and CNS treatments.
Related Reports
India Healthcare Sector Report 2026: Market Size, Structure & Where the Money Goes
MedTech Market in India 2026: Import Dependence, the PLI Reality Check, and Where Margin Actually Sits
Private Equity in Indian Healthcare 2026: Deal Trends, Valuations, and What Exits Actually Look Like
Custom Research
Need custom research on this market?
Our published reports cover broad themes. For research specific to your geography, therapy area, or competitive situation, talk to InsightRx.